SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Gensyn, the Network for Machine Intelligence, is an open infrastructure layer for AI. It provides the foundational infrastructure AI needs to operate at scale, including compute, data, and information exchange, by enabling both humans and machines to participate in open digital markets. Built with native support for AI communication, identification, and verification, Gensyn serves as the economic backbone for continual learning over new decentralised AI models and applications, without centralised control.  Gensyn is backed by a16z crypto, CoinFund, Galaxy Digital, Eden Block, Maven 11, and more. For more information, visit http://gensyn.ai

Gensyn

Gensyn is capturing significant community attention following its recent listings on major cryptocurrency exchanges, fueling investor optimism regarding its role in the decentralized AI compute sector. Traders are actively discussing the protocol's long-term potential, with many highlighting high-upside, early-stage infrastructure as a key driver for current market interest.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies is facing intense scrutiny as investors debate the impact of leadership's decision to slow Ethereum accumulation and its overall correlation with crypto market volatility. Community members are divided, with some betting on undervalued potential and share buyback programs while critics express frustration over price underperformance and dilution concerns.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following an exclusive agreement to supply the Tokyo-172 strain of BCG in the U.S., a move investors view as a pivotal strategy to bypass supply bottlenecks and accelerate Anktiva-based treatments. The community is actively discussing this news alongside leadership shakeups at the FDA, with many retail investors interpreting the alignment of supply chain control and regulatory restructuring as a significant catalyst for future growth.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings is trending as investors aggressively position themselves ahead of the upcoming earnings report, fueled by a narrative of record demand in the AI optical networking space and recent index inclusion. The community remains sharply divided between bulls betting on a sustained infrastructure supercycle and skeptics raising concerns about overvaluation and the sustainability of its parabolic rally.

Charter Communications, Inc. engages in providing broadband communications services. Its services include Spectrum TV, Spectrum Internet, and Spectrum Voice. It offers business-to-business Internet access, data networking, business telephone, video and music entertainment services, and wireless backhaul. Its advertising sales division, Spectrum Reach, offers local, regional, and national businesses the opportunity to advertise in individual and multiple service areas on cable television networks and advanced advertising platforms. The company was founded in 1993 and is headquartered in Stamford, CT.

Charter Communications Inc. - Ordinary Shares - Class A

Charter Communications is facing intense selling pressure as investors react to the stock's significant decline and ongoing concerns regarding broadband subscriber growth. While some in the community highlight the stock's low P/E valuation and aggressive share buyback strategy as signs of a potential long-term value play or short squeeze candidate, others are cautious due to the company's substantial debt load and stiff competition.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXT Inc. is trending as retail investors and traders fiercely debate the stock's parabolic climb, fueled by its central role in the supply of indium phosphide substrates essential for AI data center optical interconnects. While bulls are focused on the intense demand for photonics and infrastructure growth, many voices in the community are warning of a speculative bubble, citing concerns over insider selling, valuation metrics that appear disconnected from historical earnings, and anticipation of potential future share dilution.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is trending as investors react to Berkshire Hathaway's full exit of its position, a move that sparked significant community debate over whether the sell-off represents a strategic misstep by new leadership or a tactical portfolio rebalancing. While some traders are bracing for short-term volatility or selling into the news, many long-term holders remain bullish, viewing the pullback as a buying opportunity supported by strong fundamental growth and healthcare sector demand.

Pi Network is a social cryptocurrency and developer platform designed to make digital currency mining accessible to everyday people through mobile devices. The project aims to build a widely distributed currency that facilitates transactions for real-world goods and services rather than purely speculative trading. Its main value proposition is a mobile-first mining system that allows users to earn rewards on their phones without requiring specialized hardware, draining battery life, or using excessive data.  The network operates on the Stellar Consensus Protocol and a Federated Byzantine Agreement, which allows computers to reach agreement by trusting specific groups of other peers. Security is maintained through a global trust graph built from individual user groups called security circles where members vouch for each other. Users participate in four primary roles as pioneers, contributors, ambassadors, or nodes to ensure the network remains decentralized. This meritocratic distribution model rewards consistent engagement and network growth rather than financial wealth or technical power.  Founded by Dr. Nicolas Kokkalis and Dr. Chengdiao Fan, both of whom hold doctoral degrees from Stanford University, the project is managed by Social Chain Inc. The ecosystem includes a native wallet, a dedicated browser, and a platform for decentralized applications where the PI token is used for peer-to-peer exchange and transaction fees. Additionally, tokens can be used for purchasing goods in an internal marketplace, staking in a launchpad, or voluntary lockups that support market stability while boosting personal mining rates. The project has focused on organic community growth and does not list any external institutional investors in its documentation.

Pi Network

Pi Network is generating significant buzz as users actively discuss recent migration updates and the implications of potential exchange listings on the token's long-term utility. While some community members remain skeptical of the project's development timeline and ad-based revenue model, many proponents maintain a bullish outlook, pointing to the network's massive user base and the broader evolution of digital assets as catalysts for future value.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is trending as a primary beneficiary of a recent executive order that mandates expedited FDA review processes for psychedelic-based mental health therapies. The community is actively discussing its late-stage clinical progress and potential status as a top candidate for priority regulatory vouchers, fueling speculation about long-term valuation and future acquisition interest from major pharmaceutical players.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cash is attracting intense debate as the community navigates a period of low volume and sideways price action while waiting for key technical upgrades like the CashVM release. While some participants are frustrated by the lack of breakout momentum relative to broader crypto, others are actively accumulating based on the belief that its peer-to-peer utility and upcoming protocol improvements will lead to a major revaluation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

PDS Biotechnology Q1 2026 Earnings Call: Complete Transcript

PDS Biotechnology Corporation (NASDAQ:PDSB) Short Interest Down 16.3% in April

PDS Biotechnology Corporation (NASDAQ:PDSB - Get Free Report) was the recipient of a significant decrease in short interest during the month of April. As of April 15th, there was short interest...

PDS Biotechnology (NASDAQ:PDSB) Earns Buy Rating from HC Wainwright

HC Wainwright reaffirmed a "buy" rating and issued a $15.00 target price on shares of PDS Biotechnology in a research note on Wednesday...

Why Is PDS Biotechnology Stock Gaining Wednesday?

PDS Biotechnology says Phase 2 data show higher response rates and survival trends in colorectal cancer and prostate cancer studies.read more...

<ul class="summary-bullets"><li>The trial focused on patients with microsatellite-stable or mismatch repair-proficient metastatic colorectal cancer with liver metastases</li><li>The treatment delivered an ORR of nearly 78%, compared to 35% in a similar trial without the drug.</li><li>Two-year survival exceeded 80%, more than double the 35 - 40% seen in the comparison group.</li></ul>Shares of PDS Biotechnology (PDSB) surged 24% on Wednesday to hit their highest levels since Aug. 27, 2025, after the biotech firm reported promising Phase 2 trial results for its therapy to treat metastatic colorectal cancer.<a href="https://stocktwits.com/symbol/PDSB">PDSB stock</a> recorded its biggest intraday gains since May 26, 2023.<h2 class="st-heading-2">Early Results Show Strong Response Rate</h2>PDS Biotechnology said its investigational immunotherapy, PDS01ADC, demonstrated strong efficacy in a cohort of colorectal cancer patients. In the Phase 2 trial, the treatment delivered an objective response rate (ORR) of nearly 78%, compared to 35% in a similar trial without the drug. Two-year survival exceeded 80%, more than double the 35% to 40% seen in the comparison group.The trial focused on patients with microsatellite stable (MSS) or mismatch repair-proficient (pMMR) metastatic colorectal cancer with liver metastases. The results were published in the Journal of Clinical Oncology (JCO) Oncology Advances on March 10, 2026, the company said.“These early results showing strong tumor response rates and promising patient survival are encouraging and support our approach of subcutaneously administering PDS01ADC to activate the immune system against the cancer,” said Frank Bedu-Addo, President and CEO of PDS Biotech.<h2 class="st-heading-2">How Did Retail Traders React?</h2>One user wondered about a potential buyout, saying the company is “starting to be attractive to the big boys.”<stembedurl>https://stocktwits.com/Mr_Charlie/message/650349765</stembedurl>Another user called the update “great news.”<stembedurl>https://stocktwits.com/rwol9999/message/650343719</stembedurl>Last month, PDS Biotechnology announced updates to its Phase 3 VERSATILE-003 trial, adding progression-free survival as an interim primary endpoint, which could support faster approval of PDS0101 in HPV16-related head and neck cancer.The company also secured new patents in the U.S. and Japan, extending protection into the 2040s.Year-to-date, the stock has gained 47%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A candlestick chart can be seen in a trading platform on a smartphone. Top U.S. firms announced record buybacks this year. (Photo by Silas Stein/picture alliance via Getty Images)

PDSB Stock Hits 37-Week High — Here’s The Latest On Its Therapy To Treat Metastatic Colorectal Cancer

The biotech firm said its Phase 2 trial of PDS01ADC showed a strong objective response rate and a 24-month survival rate.

Equity

PDS Biotechnology (PDSB) Upgraded to Buy: Here's Why

PDS Biotechnology (PDSB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

<ul class="summary-bullets"><li>The company requested a meeting with the FDA to discuss an accelerated approval pathway for its lead cancer drug, PDS0101, following strong final data from its VERSATILE-002 trial.</li><li>The proposal includes amending the ongoing VERSATILE-003 Phase 3 study to add progression-free survival as an earlier primary endpoint, potentially allowing for an earlier submission.</li><li>Retail traders on Stocktwits flooded discussions with optimism, calling the stock “too cheap” and speculating that the FDA could grant early approval to give patients faster access to the therapy.</li></ul>Shares of PDS Biotechnology logged their best session in more than two months after the late-stage immunotherapy company said it has requested a meeting with the U.S. Food and Drug Administration to discuss an expedited approval pathway for PDS0101, its lead candidate in HPV16-positive head and neck cancer.<h2 class="st-heading-2">FDA Meeting Request</h2>The company said the request follows a review of the final VERSATILE-002 trial data and a proposal to amend the ongoing VERSATILE-003 Phase 3 study. The amendment would reduce the number of patients while maintaining statistical power and add progression-free survival (PFS) as an earlier primary endpoint, alongside median overall survival (mOS).If the PFS endpoint is met, it could allow for an accelerated approval submission to the FDA. While the amendment is under review, the VERSATILE-003 trial will be temporarily paused, though treatment for currently enrolled patients will continue.<h2 class="st-heading-2">Almost 40 Months Of Median Survival</h2>CEO Frank Bedu-Addo said the final survival results from VERSATILE-002 were “very exciting,” noting that it was the first trial in the recurrent or metastatic head and neck cancer population to show a median overall survival of almost 40 months. He added that seeking to include PFS as an earlier primary endpoint could shorten the trial duration.Chief Medical Officer Kirk Shepard said the company’s goal is to pursue the fastest and most cost-effective regulatory path for approval and to provide a non-chemotherapy option for patients who currently lack effective therapies.<h2 class="st-heading-2">Trial Background</h2>VERSATILE-002 is an open-label, multi-center Phase 2 trial evaluating the safety and efficacy of PDS0101, an HPV16-targeted immunotherapy, in combination with pembrolizumab for unresectable, recurrent or metastatic HPV16-positive head and neck cancer.On Stocktwits, retail sentiment for PDS Biotechnology was ‘extremely bullish’ amid a 2,333% surge in 24-hour message volume.<h2 class="st-heading-2">Stocktwits Bulls Bet On Early FDA Nod</h2>One user said the news was “very good” and that the stock looked “way too cheap,” suggesting they were watching for more upside.<stembedurl>https://stocktwits.com/makedatbread88/message/634249334</stembedurl>Another user speculated that the FDA might allow an early approval if PDS agreed to continue trials at the same time, calling it a move that could give very sick head and neck cancer patients access to a potentially life-saving therapy.<stembedurl>https://stocktwits.com/Stockman824/message/634214470</stembedurl><a href="https://stocktwits.com/symbol/PDSB">PDS Biotechnology’s stock</a> has declined 38% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

PDS Biotechnology’s stock (PDSB) has declined 38% so far in 2025. | Image source: Getty Images

PDS Biotechnology Stock Logs Best Session In 2 Months After FDA Fast-Track Push For Cancer Drug — Retail Bets On Early Approval

The company requested a meeting with the FDA to discuss an accelerated approval pathway for its lead cancer drug, PDS0101, following strong final data from its VERSATILE-002 trial.

<ul class="summary-bullets"><li>Q3 revenue of $995.7 million beat Align’s own forecast range of $965 million to $985 million, fueled by strong growth in clear aligners for teens and kids.</li><li>Non-GAAP earnings rose to $2.61 per share, with operating margins improving despite restructuring and impairment charges.</li><li>Retail traders on Stocktwits turned bullish, setting upside targets between $170 and $200 for the stock.</li></ul>Shares of Align Technology rose about 16% in after-hours trading on Wednesday after the Invisalign maker reported third-quarter (Q3) revenue above its own forecast and showed improving momentum in clear aligners for teens and kids.<h2 class="st-heading-2">Results Beat Company Outlook</h2>Align reported Q3 revenue of $995.7 million, up 1.8% year over year and above its guidance range of $965 million to $985 million, though down 1.7% from the prior quarter as the company had flagged. Currency helped, adding about $15.6 million year on year.Clear Aligner revenue was $805.8 million, up 2.4% from a year earlier and flat sequentially. Total clear aligner volume rose 4.9% to 647,800 cases, with the biggest tailwind from younger patients.Treatments for teens and kids jumped 8.3% year over year and 14.7% from Q2 to 256,000 cases, helped by more doctors submitting cases and continued adoption of Invisalign First.The Imaging Systems and CAD/CAM business, which includes iTero scanners, brought in $189.9 million, down 0.6% year over year and 8.6% sequentially, which the company said was normal Q3 capital-equipment seasonality.<h2 class="st-heading-2">Profitability&nbsp;</h2>GAAP operating income was $96.3 million for an operating margin of 9.7%, lower than last year, mainly because the quarter included $88.3 million of restructuring, impairment and accelerated depreciation charges. On a non-GAAP basis, operating margin improved to 23.9%.Net income fell to $56.8 million, or $0.78 per share, from $1.55 a year earlier, largely because of those one-time charges. Non-GAAP EPS was $2.61, up from $2.35.Align ended the quarter with $1 billion in cash and cash equivalents, up from $901 million in the second quarter (Q2).<h2 class="st-heading-2">Outlook</h2>For the fourth quarter (Q4), Align expects revenue of $1.025 billion to $1.045 billion, with clear aligner volume, ASP and systems revenue all seen improving sequentially, and non-GAAP operating margin around 26%.&nbsp;For full-year 2025, the company still expects clear aligner volume to grow in the mid-single digits and revenue to be flat to slightly higher than 2024, reflecting a mixed dental market, especially in North America.<h2 class="st-heading-2">Stocktwits Users Cheer Align’s Strong Quarter</h2>On Stocktwits, retail sentiment for Align was ‘bullish’ amid ‘extremely high’ message volume.One user said Align remains the clear market leader after the quarter and that they were bullish on the stock getting back above $170 by year-end, with a price target of $200 by the first quarter of 2026.&nbsp;<stembedurl>https://stocktwits.com/durocali/message/634224575</stembedurl>Another user said the print was a big beat and flagged $155 as the level to watch on the upside, noting there were still higher gaps to be filled.<stembedurl>https://stocktwits.com/SpudZone/message/634224376</stembedurl><a href="https://stocktwits.com/symbol/ALGN">Align’s stock</a> has declined 37% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Align Technology logo is displayed on a smartphone with a S&P index website background. (Photo Illustration by Alvin Chan/SOPA Images/LightRocket via Getty Images)

Align Technology Stock Surges After-Hours On Teen Demand — Retail Sees Rally Ahead Into 2026

Q3 revenue of $995.7 million beat Align’s own forecast range of $965 million to $985 million, fueled by strong growth in clear aligners for teens and kids.

Take the Zacks Approach to Beat the Markets: StoneCo, Axon, Intuit in Focus

Shares of PDS Biotechnology Corporation (PDSB) drew investor attention on Thursday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.pdsbiotech.com/index.php/investors/news-center/press-releases/press-releases1/132-2025-news/980-iotecheportsullear2024inancialesultsandr20250327">reported</a> better-than-feared losses for 2024.PDS Biotechnology reported a loss per share of $1.03 for the year, narrower than the $1.39 reported for 2023 and better than an analyst estimate of $1.11, according to FinChat data.Net loss narrowed to $37.61 million in 2024 compared to $42.94 million in the prior year.The reduced losses, the company said, were primarily due to a decrease in operating expenses.Research and development expenses fell during the year to $22.6 million from $27.8 million a year ago, owing to reduced clinical costs, personnel costs, and professional fees.The company ended the year with a cash balance of $41.7 million.Last month, PDS Biotechnology announced an up to $22 million registered direct offering. The company said the securities purchase agreements with new and existing healthcare-focused institutional investors included $11 million of upfront gross proceeds.It also included up to an additional $11 million of aggregate gross proceeds upon cash exercise in full of warrants issued to the investors.PDS is a late-stage immunotherapy company developing investigational products designed to stimulate and enhance targeted T cell responses against cancers.Earlier this month, the company said that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application to evaluate a combination of its investigational immunotherapy candidate Versamune MUC1 with a novel investigational tumor-targeting Interleukin 12 to treat colorectal carcinoma in certain patients who failed previous treatment.On Stocktwits, the retail investor sentiment about PDS Biotechnology dropped further into the ‘bearish’ territory (32/100), while message volume remained at the ‘extremely low’ level over the past 24 hours.<figure class="image"><img style="aspect-ratio:647/151;" src="https://news.stocktwits-cdn.com/Screenshot_2025_03_27_at_12_26_56_PM_png_6c503f4d3f.webp" alt="PDSB's Sentiment Meter and Message Volume as of 12:27 p.m. ET on March 27, 2025 | Source: Stocktwits" width="647" height="151"><figcaption>PDSB's Sentiment Meter and Message Volume as of 12:27 p.m. ET on March 27, 2025 | Source: Stocktwits</figcaption></figure>After the company released its earnings report, HC Wainwright analyst Joseph Pantginis lowered the firm’s price target to $13 from $21 while keeping a ‘Buy’ rating on the shares.A Stocktwits user, however, expressed optimism on the company.<stembedurl>https://stocktwits.com/AyR15/message/609402462</stembedurl>Another user opined that the results were “not as bad as predicted.”<stembedurl>https://stocktwits.com/Mr_Charlie/message/609407057</stembedurl><a href="https://stocktwits.com/symbol/PDSB">PDSB shares</a> have lost over 25% this year and over 65% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/toncoin-gains-outpace-bitcoin-ethereum-after-musk-grok-ai-goes-beyond-x-to-telegram/chJ2BLTRbEJ">Toncoin Gains Outpace Bitcoin, Ethereum After Musk’s Grok AI Goes Beyond X To Telegram – Retail’s Divided</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

PDS Biotechnology Stock In Spotlight On Better-Than-Feared 2024 Loss – Retail Stays Bearish

The company said the reduced losses were primarily due to decreased operating expenses.  

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products include PDS0101 and PDS01ADC. The company was founded by Frank K. Bedu-Addo in 2005 and is headquartered in Princeton, NJ.

PDSB
PDS Biotechnology Corporation

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Latest PDSB News

PDSBPDS Biotechnology Corporation